World's Best Scientists 2026 revealed!
Lawrence H. Einhorn

Lawrence H. Einhorn

D-Index & Metrics

Medicine

D-Index
134
Citations
65415
World Ranking
2154
National Ranking
1216

Lawrence H. Einhorn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Lawrence H. Einhorn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 767 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Lawrence H. Einhorn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Lawrence H. Einhorn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 134 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2001 - Member of the National Academy of Sciences
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Lawrence H. Einhorn is primarily affiliated with Indiana University in the United States. Their research career has focused extensively on medicine, with a particular emphasis on surgery, pulmonary and respiratory medicine, neurology, oncology, and genetics.

Their main topics of study include testicular diseases and treatments, sarcoma diagnosis and treatment, neuroblastoma research and treatments, urologic and reproductive health conditions, glioma diagnosis and treatment, cancer treatment and pharmacology, and cancer genomics and diagnostics.

They have contributed to a significant number of publications, particularly in the following venues:

  • Journal of Clinical Oncology (60 publications)
  • The Journal of Urology (9 publications)
  • Cancer Medicine (4 publications)
  • UNC Libraries (4 publications)
  • Cancer Research (3 publications)

Among their recent published papers are:

  • "Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153" (2020, Journal of Clinical Oncology)
  • "Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy" (2023, Journal of Clinical Oncology)
  • "Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors" (2020, European Urology)
  • "A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors" (2022, Investigational New Drugs)
  • "Testicular Cancer: Biology to Bedside" (2021, Cancer Research)

Frequent coauthors in their work include:

  • Nabil Adra
  • Nasser H. Hanna
  • Sandra K. Althouse
  • Clint Cary
  • Timothy A. Masterson

Lawrence H. Einhorn has been recognized by their peers through membership in notable scientific organizations, specifically as a member of the National Academy of Sciences since 2001 and as a member of the Association of American Physicians.

Best Publications

  • Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

    Nasser Hanna;Frances A. Shepherd;Frank V. Fossella;Jose R. Pereira

  • Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer

    Lawrence H. Einhorn;John Donohue

  • Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

    S D Williams;S D Williams;R Birch;R Birch;L H Einhorn;L Irwin;L Irwin

  • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    P J Loehrer;L H Einhorn;P J Elson;E D Crawford

  • Drugs five years later. Cisplatin.

    Patrick Loehrer;Lawrence Einhorn

  • Recommendations on the Use of 18F-FDG PET in Oncology

    James W. Fletcher;James W. Fletcher;Benjamin Djulbegovic;Heloisa P. Soares;Barry A. Siegel

  • Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

    Alan B. Sandler;J. Nemunaitis;C. Denham;J. Von Pawel

  • Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

  • Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

    F. Roila;J. Herrstedt;M. Aapro;R. J. Gralla

  • Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

    Janice L. Gabrilove;Charles S. Cleeland;Robert B. Livingston;Brenda Sarokhan

  • Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

    Nasser Hanna;Paul A. Bunn;Corey Langer;Lawrence Einhorn

  • A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

    C Jacobs;G Lyman;E Velez-García;K S Sridhar

  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

    B J Roth;D H Johnson;L H Einhorn;L P Schacter

  • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    S B Saxman;K J Propert;L H Einhorn;E D Crawford

  • Treatment of testicular cancer: a new and improved model.

    L H Einhorn

  • Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

    Nasser Hanna;Marcus Neubauer;Constantin Yiannoutsos;Ronald McGarry

  • Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis

    Carsten Bokemeyer;Craig R. Nichols;Jean P. Droz;Hans J. Schmoll

  • High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors

    Lawrence H. Einhorn;Stephen D. Williams;Amy Chamness;Mary J. Brames

  • Recommendations on the Use of 18 F-FDG PET in Oncology

    James W. Fletcher;Benjamin Djulbegovic;Heloisa P. Soares;Barry A. Siegel

  • Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

Frequent Co-Authors

Patrick J. Loehrer
Patrick J. Loehrer Indiana University
Sophie D. Fosså
Sophie D. Fosså Oslo University Hospital
Robert Huddart
Robert Huddart Institute of Cancer Research
Howard D. Sesso
Howard D. Sesso Harvard Medical School
M. Eileen Dolan
M. Eileen Dolan University of Chicago
Christian Kollmannsberger
Christian Kollmannsberger University of British Columbia
Thomas M. Ulbright
Thomas M. Ulbright Indiana University
Christopher Sweeney
Christopher Sweeney Harvard University
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Eric R. Gamazon
Eric R. Gamazon Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical education in the USA opens doors to a variety of online degrees and career pathways. For those interested in healthcare management, pursuing one of the best online mha programs can prepare you for leadership roles in hospitals and health systems, offering flexibility for working professionals.

Registered nurses looking to advance their qualifications without traditional in-person clinicals can consider an rn to bsn online with no clinicals program. These programs are tailored to help RNs earn a bachelor's degree efficiently while balancing work and personal responsibilities.

For nurses aspiring to the very top of clinical practice, there are options for both accelerated and more flexible doctoral programs. Those seeking quick advancement can look for some of the shortest dnp programs online, which enable completion in an expedited timeframe. Alternatively, applicants needing a manageable workload may explore the easiest dnp programs to find courses designed for accessibility and work-life balance.

Whether your goal is to move into management, advance your nursing credentials, or specialize at the doctoral level, there are tailored online pathways to fit your needs and career aspirations.

Best Scientists Citing Lawrence H. Einhorn

Trending Scientists

Recently Published Articles